Rapidly growing Novadip Biologicals now counts a staff of around 45 dedicated professionals, covering Administration and Finance, Quality Control, Manufacturing Operations, R&D, Quality Assurance, Regulatory Affairs & Intellectual Property and Clinical.
Novadip’s management team is composed of professionals in cell-therapy and regenerative medecine. Each shares the same passion for excellence in medecine and finding solutions that answer unmet medical needs.
Chief Executive Officer
Jeff was elected as President and Chief Executive Officer in early 2019. Prior to joining Novadip, Jeff was president and CEO of Argos Therapeutics, a role he held from 2010 to 2018. He joined Argos in 2002, leading the company’s business development efforts until becoming president and chief executive officer. He led the company through completion of a phase 3 trial, raised over $250 million in equity financings, including an initial public offering on Nasdaq, and completed numerous partnering transactions with international biopharmaceutical companies. Jeff received a bachelor’s degree from Brown University and Master of Business Administration and Juris Doctor degrees from the University of Virginia.
Chief Scientific Officer and co-founder
Denis has a strong expertise in the fields of tissue and cell banking, development of advanced cell therapies for regenerative medicine and preclinical to clinical technology transfer respecting cell transplantation regulations. He completed his medical degree in 2000 and a doctorate in biomedical sciences (orientation: cell therapy) in 2006 at the University catholique de Louvain. In 2001, he started his career in the field of cell therapy (Prof. JP Squifflet, St. Luc University Hospital), becoming head of the Endocrine Cell Therapy Unit – St. Luc University Hospital after only a few years. In 2009, he was appointed head of the Musculoskeletal Tissue bank (St. Luc University Hospital) and was put in charge of the Tissue/Cells Therapy Centre (St. Luc University Hospital) in 2012. In 2014, he became a member of the Belgium Superior Health Council. Denis has published more than 46 manuscripts in peer-reviewed journals, presented at 40 lectures, and has more than 120 communications with more than 1300 citations. He is a reviewer and member of the editorial boards of scientific and medical peer-reviewed journals. He has also received numerous awards. In 2013, he co-founded Novadip biosciences and joined the company as Chief Scientific Officer in 2015.
Chief Medical Officer
Beatrice is a specialist in pharmaceutical medicine actively involved in developing novel therapies such as ATMP (advanced therapy medicinal products) based on stem cell technology, small molecules in immuno-oncology and vector vaccines for infectious diseases. After obtaining her medical degree, Beatrice was awarded a Doctor in Medical Sciences degree in 1984. For the past 25 years, she has worked in leading positions in the clinical research and medical affairs departments of major international pharmaceutical companies, including Wyeth-Ayerst R&D, GSK Biologicals and Sanofi Pasteur. She is the author or co-author of multiple publications in international peer-reviewed journals and books, a lecturer at several congresses, an advisor to several national and international companies and NGOs, and a member of data safety monitoring boards and scientific advisory boards. Today, she is managing director of her own consultancy firm (Bejamad). In 2016, Beatrice joined Novadip biosciences as Clinical Medical Officer.”
Head of Finance and Administration
Virginie holds a Master in Business Administration from UCL and a Master in Accounting and Audit from KUL, complemented by a Management degree for the Pharmaceutical sector. Virginie started her career with Deloitte in 2003, where she acquired a deep knowledge of finance and accounting across various industries. In 2006, she joined the pharmaceutical sector, including AstraZeneca and AbbVie, in different positions within both Belgium affiliates and European headquarters. Her major contribution was to develop the finance department as a close partner of the R&D, regulatory, market access and commercial teams. In 2015, Virginie joined Novadip Biosciences as Head of Finance and Administration.
Chief RA/IP Officer
Roland joined Novadip since its inception. He started his career in 1997 in clinical affairs with Bristol-Myers Squibb Int. Corp. where he received a president award for his contribution. He then joined the regulatory affairs Europe dept. to focus on marketing approval of novel pharmaceuticals. As of 2002, he specialized in blood-derived products and biologicals notably with Navigant Biotechnologies Inc. where he served as head of regulatory and governmental affairs. In 2008, he joined Cardio3 Biosciences (now Celyad) and was instrumental in making this start-up stem cell company a first-in class player in the discovery and development regenerative and protective therapies. Roland holds a Master of Science in Biological Sciences and a Doctorate in Biophysics from the Free University of Brussels and is co-inventor of several patent families.
Chief Operating Officer
Nicolas joined Novadip Biosciences in November 2015. He is in charge of Novadip’s Pharmaceutical Operations including Manufacturing, Quality Control and Quality Assurance departments. For the past 15 years, Nicolas specialized in stem cell technology and gained significant expertise in biochemistry and mechanisms of cellular differentiation. He holds a PhD in Life Sciences from the Université Catholique de Louvain (UCL) in Belgium and did postdoctoral studies at the Université Libre de Bruxelles, the University of Glasgow and UCL. From 2003 to 2010, he worked on the cellular and molecular mechanisms leading to a predisposition to develop diabetes and was involved in experimental medicine research programs. In 2011, Nicolas joined Quality Assistance, a CRO acting for international biopharmaceutical companies, where he was the head of a centralised analytical support dedicated to Cell-Based Medicinal Products. Through the management of numerous projects from the discovery phase to and including the development and validation of release testing assays, Nicolas has gained experience in biopharmaceutical development strategies applied to regenerative medicine. Since 2008, Nicolas is invited lecturer in several high schools and colleges.